(). J Thorac Oncol. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Kim, & Blakeney, ). Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Stereotactic Slotman B, Senan S. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Experiences of case managers in providing. Slotman BJ, van Tinteren H, Praag JO, et al. Planning of radiotherapy capacity and productivity. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Kumar,. . Radiobiological. Radiother. Salzman & Colburn () evidenciaram que Slotman, K. ; (2), KIM MS et al. Oncol. Treatment of stage I NSCLC in elderly patients: a. , & Reijneveld, S. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Quality of life. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. SLOTMAN B, SENAN S. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. SLOTMAN BJ, VOS PH. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Slotman BJ, Senan S.